Top Markets
#1 ADO Protocol ADO Protocol +193.34%
#2 Islamic Coin Islamic Coin +155.37%
#3 GoPlus Security GoPlus Security +44.27%
#4 GAIB AID GAIB AID +24.67%
#5 SkyAI SkyAI +14.39%
#6 Verus Coin Verus Coin +13.64%
#7 o1.exchange o1.exchange +12.71%
#8 Tutorial Tutorial +12.27%
#9 Casper Network Casper Network +12.23%
#10 Pons Pons +12.22%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Apimeds Pharmaceuticals US, Inc Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc

APUS
Rank in Stocks #33689
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage... Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Share Price
$4.70
Last synced: 2026-08-14
Market Cap
$7.09M
Change (1 day)
-0.21%
Change (1 year)
-70.63%
Country
US
Trade Apimeds Pharmaceuticals US, Inc (APUS)

Category

Healthcare
Revenue for Apimeds Pharmaceuticals US, Inc (APUS)
Revenue in Aug 2026 TTM: 0
According to Apimeds Pharmaceuticals US, Inc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Apimeds Pharmaceuticals US, Inc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE